title: Epidemiologic approach to open-angle glaucoma: 2. Survival analysis of adverse drug reactions. Report of the Canadian Ocular Adverse Drug Reaction Registry Program. The Collaborative Glaucoma Study Group.
abstract: Medical treatment, intraocular pressure (IOP) and adverse drug reactions were recorded in a prospective multicentre study of 71 unselected, newly diagnosed cases of open-angle glaucoma. Eight ophthalmologists recorded standard information at five visits over a mean interval of 12.1 months. No limitations were imposed on the choice of drugs or interval between visits. The IOP was satisfactorily controlled throughout the follow-up period with the first drug prescribed in 36% of eyes. In an additional 10% to 13% the IOP was stabilized with alternative therapy, prescribed for approximately one-third of eyes per visit. A total of 27 patients reported 18 severe and 31 mild suspected adverse reactions during the follow-up period. Survival analysis showed that there was no significant difference between the proportions of patients continuing treatment with the first, second and third drug prescribed (half-life of treatment approximately 210 days in all three cases). However, when only changes for unsatisfactory pressure were considered, the half-life of treatment was significantly longer, 350 days (p = 0.02).
authors.affiliation: Department of Ophthalmology, University of British Columbia, Vancouver.
authors.forename: I S
authors.initials: IS
authors.lastname: Begg
authors.forename: R W
authors.initials: RW
authors.lastname: Cottle
mesh_terms: D000086:Acetazolamide / Q000009:adverse effects; D000328:Adult; D000367:Age Factors; D000368:Aged; D004837:Epinephrine / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009883:Ophthalmic Solutions / Q000009:adverse effects*; D010862:Pilocarpine / Q000009:adverse effects; D013997:Time Factors; D013999:Timolol / Q000009:adverse effects
chemical_list: D009883:Ophthalmic Solutions; D010862:Pilocarpine; D013999:Timolol; C015173:dipivefrin; C018285:epinephryl borate; D000086:Acetazolamide; D004837:Epinephrine